LU86930A1 - Utilisation de gangliosides exogenes dens des maladies tumorales comme facteur de protection contre la toxite de medicaments antitumoraux - Google Patents

Utilisation de gangliosides exogenes dens des maladies tumorales comme facteur de protection contre la toxite de medicaments antitumoraux Download PDF

Info

Publication number
LU86930A1
LU86930A1 LU86930A LU86930A LU86930A1 LU 86930 A1 LU86930 A1 LU 86930A1 LU 86930 A LU86930 A LU 86930A LU 86930 A LU86930 A LU 86930A LU 86930 A1 LU86930 A1 LU 86930A1
Authority
LU
Luxembourg
Prior art keywords
gangliosides
mixture
vincristine
agent
antineoplastic
Prior art date
Application number
LU86930A
Other languages
English (en)
French (fr)
Inventor
Valle Francesco Della
Original Assignee
Fidia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fidia Spa filed Critical Fidia Spa
Publication of LU86930A1 publication Critical patent/LU86930A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU86930A 1986-06-30 1987-06-25 Utilisation de gangliosides exogenes dens des maladies tumorales comme facteur de protection contre la toxite de medicaments antitumoraux LU86930A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT8648203A IT1208751B (it) 1986-06-30 1986-06-30 Possibile uso dei gangliosidi esogeni in malattie tumorali come fattore protettivo contro la neurotossicita' da farmaci antitumorali
IT4820386 1986-06-30

Publications (1)

Publication Number Publication Date
LU86930A1 true LU86930A1 (fr) 1987-11-11

Family

ID=11265194

Family Applications (1)

Application Number Title Priority Date Filing Date
LU86930A LU86930A1 (fr) 1986-06-30 1987-06-25 Utilisation de gangliosides exogenes dens des maladies tumorales comme facteur de protection contre la toxite de medicaments antitumoraux

Country Status (16)

Country Link
US (1) US5229373A (de)
EP (1) EP0251298B1 (de)
JP (1) JPS6327434A (de)
AT (1) ATE69381T1 (de)
AU (1) AU601988B2 (de)
BE (1) BE1000723A4 (de)
CA (1) CA1314219C (de)
DE (2) DE3774501D1 (de)
DK (1) DK165621C (de)
ES (1) ES2038621T3 (de)
FR (1) FR2601248B1 (de)
GR (2) GR871005B (de)
IL (1) IL82944A (de)
IT (1) IT1208751B (de)
LU (1) LU86930A1 (de)
ZA (1) ZA874597B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1254280B (it) * 1992-03-13 1995-09-14 Fidia Spa Composizioni farmaceutiche comprendenti monosialoganglioside gm1 o un suo derivato atte al trattamento della malattia di parkinson
US6765087B1 (en) * 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4430041A1 (de) † 1994-08-24 1996-02-29 Milupa Ag Allergieprotektive Formelnahrung
US5567684A (en) * 1994-09-14 1996-10-22 The Regents Of The University Of California Synthetic ganglioside derivatives
AU2002326805B2 (en) 2001-08-29 2009-01-22 Seneb Biosciences, Inc. Novel synthetic ganglioside derivatives and compositions thereof
NZ542148A (en) 2003-03-06 2008-05-30 Neose Technologies Inc Methods and compositions for the enzymatic synthesis of gangliosides
EP2282723A2 (de) * 2008-03-26 2011-02-16 University of Oxford Liposome mit endoplasmischem retikulum als target
US20120035120A1 (en) 2009-03-25 2012-02-09 Seneb Biosciences, Inc. Glycolipids as treatment for disease
US20120148547A1 (en) * 2009-09-01 2012-06-14 Hadasit Medical Reasearch Services & Development Ltd. Combination of vitamin e and beta-glycosphingolipids in compositions and methods for preventing and treating hepatic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1168205B (it) * 1983-07-21 1987-05-20 Wellcome Italia Derivato di monsialo ganglioside dotato di attivita' antibatterica, antifungina ed antitumorale, composizioni che lo contengono e procedimento per la loro preparazione
IT1182209B (it) * 1985-02-18 1987-09-30 Fidia Farmaceutici Uso terapeutico del monosialoganglioside gm1 e dei suoi derivati in gravi patologie di infarti cerebrali

Also Published As

Publication number Publication date
AU7490887A (en) 1988-01-07
ES2038621T3 (es) 1993-08-01
DK333787D0 (da) 1987-06-29
BE1000723A4 (fr) 1989-03-21
DE3774501D1 (de) 1991-12-19
DK333787A (da) 1987-12-31
GR871005B (en) 1987-10-23
EP0251298B1 (de) 1991-11-13
ATE69381T1 (de) 1991-11-15
US5229373A (en) 1993-07-20
FR2601248B1 (fr) 1989-08-25
IL82944A (en) 1993-04-04
DK165621C (da) 1993-06-01
JPS6327434A (ja) 1988-02-05
DE3721562A1 (de) 1988-03-03
AU601988B2 (en) 1990-09-27
IT8648203A0 (it) 1986-06-30
ZA874597B (en) 1988-03-30
EP0251298A2 (de) 1988-01-07
CA1314219C (en) 1993-03-09
FR2601248A1 (fr) 1988-01-15
GR3003790T3 (de) 1993-03-16
IT1208751B (it) 1989-07-10
EP0251298A3 (en) 1988-10-26
DK165621B (da) 1992-12-28

Similar Documents

Publication Publication Date Title
JPH08500589A (ja) アストラガルス ポリサッカライド免疫調節剤
LU85974A1 (fr) Melange de gangliosides utile comme instrument therapeutique d'elimination d'effets douloureux de neuropathies peripheriques
US4940694A (en) Therapeutic use of GM1 in severe cerebral ischemic strokes pathologies
Manik et al. Anti-diabetic and antihyperlipidemic effect of allopolyherbal formulation in OGTT and STZ-induced diabetic rat model
LU86930A1 (fr) Utilisation de gangliosides exogenes dens des maladies tumorales comme facteur de protection contre la toxite de medicaments antitumoraux
CA2749931C (en) Use of pterosin compounds for treating diabetes and obesity
EP2931295B1 (de) Algenextrakt mit sulfatierten und nicht-sulfatierten polyanionischen polysacchariden und verwendung davon
US4910224A (en) Method of modifying the lipid structure and function of cell membranes and pharmaceutical compositions for use therein
CA3090394A1 (en) Methods for treating mitochondrial disorders
Reynolds et al. Dopamine metabolism in human brain: effects of monoamine oxidase inhibition in vitro by (—) deprenyl and (+) and (—) tranylcypromine
CA2045982A1 (en) Use of the gm monosialoganglioside and of its internal ester derivative to prevent the insurgence in man of the
DE69330842T2 (de) Verwendung von Monosialogangliosid GMl oder von N-Dichlor-Acetyl-lyso-GMl zur Vorbeugung oder zur Umkehrung der von einer Langzeitbehandlung mit L-DOPA bei der Therapie von Morbus Parkinson induzierten neuronale Degeneration
EP1035858A1 (de) Verwendung von gingko biloba extrakten zur herstellung eines medikaments
EP1207878B1 (de) Behandlung der migräne durch verabreichung von alpha-liponsäure oder derivaten derselben
CA2716764C (fr) Nouvelle utilisation de n-acetyl-taurinate de zinc
GRECO et al. Cycloleucine encephalopathy
Samson GM1 ganglioside treatment of central nervous system injury: Clinical evidence for improved recovery
KR100485936B1 (ko) 진세노사이드 Rh2 및 Rg3 항암 조성물
DE102006019907A1 (de) Verwendung von substituierten Glycerinderivaten zur Herstellung einer pharmazeutischen Zubereitung
EP1289515B1 (de) Pharmazeutische zusammensetzung die ein polymer assoziert oder konjugiert an einem salz einer phenylalkylcarboxylsäure enthält; die konjugierte polymere und ihre anwendungen
Jiang et al. Roles and mechanisms of fucoidan against dermatitis: A review
IMAMOTO et al. Effect of neonatal administrations of 6-OHDA on the brain development I. Alteration in the striatum
EP0493861A2 (de) Nicotinamid-adenin-dinukleodid enthaltendes Antidepressionsmittel
Rybalkina et al. Correction of the toxic effect of cyclophosphamide on hemopoiesis in animals with lewis lung carcinoma using low-molecular-weight sodium alginate
KR100458996B1 (ko) 뇌기능개선제

Legal Events

Date Code Title Description
DT Application date
TA Annual fee